Metformin Year-1 Outcomes: What Real Users Actually Experience

What a first year on metformin looks like

Metformin is an oral biguanide, prescription-only, and labeled for type 2 diabetes in adults, plus children 10 and older for the immediate-release tablets [1]. Metformin is available by prescription. The first year has been measured in two settings: the label's own trials, which recorded side effects [1][4], and the Diabetes Prevention Program. In the Diabetes Prevention Program, people assigned metformin took 850 mg twice daily; investigators tracked diabetes incidence and weight, while a later analysis measured vitamin B12 [5][2][6].

The gut side effects reported in trials

In a US trial of immediate-release metformin at doses up to 2,550 mg a day, 141 people received metformin and 145 received placebo [1]. Diarrhea occurred in 53% versus 12%, nausea or vomiting in 26% versus 8%, flatulence in 12% versus 6%, and indigestion in 7% versus 4%; headache was reported by 6% versus 5% [1]. Diarrhea led 6% of metformin-treated patients to stop the drug, and taste disorder was reported by 1% to 5% [1].

The extended-release label reports lower-looking rates. Across placebo-controlled trials of extended-release metformin (781 patients on metformin, 195 on placebo), diarrhea occurred in 10% versus 3%, nausea or vomiting in 7% versus 2%, and diarrhea led to discontinuation in 0.6% [4]. The label itself cautions that adverse reaction rates from different trials cannot be directly compared, so these two sets of numbers are not a head-to-head test of the two formulations [4].

What changes with time is documented in the DPP: gastrointestinal symptoms were more common in metformin than placebo participants and declined over time, and no significant safety issues were identified [2].

Weight in the first year

During the double-blind DPP, weight fell 2.06% with metformin versus 0.02% with placebo, and waist circumference fell 2.13 cm versus 0.79 cm [2]. Averages hide a lot. Among DPP participants, 28.5% of the metformin group, 62.6% of the intensive lifestyle group and 13.4% of the placebo group lost at least 5% of their body weight in the first year [3]. The magnitude of weight loss during the double-blind period was directly related to adherence [2].

The DPP enrolled people with elevated fasting and post-load glucose, not people with type 2 diabetes, and used 850 mg twice daily [5]. In a later analysis of participants who had lost at least 5% of body weight in year one, mean weight loss maintained between years 6 and 15 was 6.2% in the metformin group, 3.7% in the intensive lifestyle group and 2.8% in the placebo group; that analysis looked at non-randomized subsets and does not show metformin causes more weight loss than lifestyle change for everyone [3].

Blood sugar and diabetes risk

The DPP assigned 3,234 adults at high risk of diabetes to placebo, metformin 850 mg twice daily, or a lifestyle program targeting 7% weight loss and 150 minutes of activity a week. Average follow-up was 2.8 years [5]. Diabetes incidence was 11.0 cases per 100 person-years on placebo, 7.8 on metformin and 4.8 on lifestyle: metformin cut incidence by 31% (95% CI 17 to 43%) and lifestyle by 58% (48 to 66%) [5].

At 15 years, the metformin advantage had shrunk to 18% (HR 0.82), and cumulative diabetes incidence was 55% with lifestyle, 56% with metformin and 62% with placebo. There was no overall difference in microvascular disease (placebo 12.4%, metformin 13.0%, lifestyle 11.3%) [7].

In UKPDS 34, which studied overweight patients with newly diagnosed type 2 diabetes, median HbA1c was 7.4% on metformin versus 8.0% on conventional diet over a median 10.7 years, with risk reductions of 32% for any diabetes-related endpoint (95% CI 13 to 47) and 36% for all-cause mortality (9 to 55) [8]. Metformin showed a greater effect than chlorpropamide, glibenclamide or insulin for any diabetes-related endpoint, all-cause mortality and stroke [8]. Ten years after the trial ended, the overweight metformin group still showed risk reductions of 21% for any diabetes-related endpoint, 33% for myocardial infarction and 27% for death from any cause [9]. The label also states that conclusive evidence of macrovascular risk reduction with metformin has not been established in clinical studies [1].

Vitamin B12 and blood counts

The label's B12 warning is specific: in metformin clinical trials of 29-week duration, a decrease to subnormal levels of previously normal serum vitamin B12 was seen in approximately 7% of patients, possibly through interference with B12 absorption from the B12-intrinsic factor complex, and the label directs measuring hematologic parameters annually and vitamin B12 at 2 to 3 year intervals [1].

In the DPP/DPPOS, low B12 (203 pg/mL or less) occurred in 4.3% of metformin versus 2.3% of placebo participants at 5 years (7.4% versus 5.4% at 13 years, not a significant difference), and combined low plus borderline-low B12 (298 pg/mL or less) in 19.1% versus 9.5% at 5 years and 20.3% versus 15.6% at 13 years [6]. The odds of deficiency rose 13% for each year of metformin use (OR 1.13, 95% CI 1.06 to 1.20), anemia was more common with metformin but did not track B12 status, and neuropathy was more common in metformin users with low B12 [6]. In the DPP itself, hemoglobin and hematocrit were slightly lower on metformin, with the fall occurring in the first year and no further change afterward [2].

What the label says to watch for

Metformin carries a boxed warning for lactic acidosis. Postmarketing cases have included fatal ones, with subtle, nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence and abdominal pain, and a laboratory picture of lactate above 5 mmol/L, anion gap acidosis and metformin levels generally above 5 mcg/mL [1]. The label says these cases primarily occurred in patients with significant renal impairment and lists age 65 or older, radiologic contrast studies, surgery and other procedures, hypoxic states such as acute congestive heart failure, excessive alcohol intake, hepatic impairment and mitochondrial disease as risk factors [1].

On kidneys, the label directs checking eGFR before starting and at least annually; metformin is contraindicated below 30, starting is not recommended at 30 to 45, and if eGFR falls below 45 the benefit and risk of continuing should be assessed [1]. For iodinated contrast, the label says to stop metformin at the time of or before the procedure in patients with eGFR between 30 and 60, a history of hepatic impairment, alcoholism or heart failure, or when intra-arterial contrast is used, then recheck eGFR 48 hours later and restart only if renal function is stable [1]. Alcohol potentiates metformin's effect on lactate metabolism, and the label warns against excessive intake [1]. Hypoglycemia risk rises when metformin is combined with insulin or an insulin secretagogue, and lower doses of those may be needed [1].

Who may respond less

OCT1 variants may contribute to differences in glucose response to metformin, but the study does not show how much they affect a person's first year [11]. Reduced-function variants in the transporter, which carries metformin into liver cells, were associated with significantly smaller glucose-lowering effects in glucose tolerance tests, and the OCT1-420del variant has an allele frequency of about 20% in white Americans [11]. Kidney function limits dose, since starting metformin is not recommended at an eGFR of 30 to 45 [1]. Adherence matters too: weight loss in the DPP was directly related to adherence [2].

Dosing schedule in the labels

The immediate-release label's schedule starts at 500 mg twice daily or 850 mg once daily with meals, increasing by 500 mg weekly or 850 mg every 2 weeks to a maximum of 2,550 mg a day, with doses above 2,000 mg possibly better tolerated three times daily [1]. The extended-release label says the tablets are to be swallowed whole and never crushed, cut or chewed, with a start of 500 mg once daily with the evening meal, increased by 500 mg weekly to a maximum of 2,000 mg once daily [4].

What the reviews do not tell you

Individual online posts cannot provide a verified estimate of first-year outcomes. The percentages in this article come from clinical trials and the prescribing labels.